Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Local Institution, Brussels

Local Institution, B-leuven

Local Institution, Heidelberg

Local Institution, Woodville

Local Institution, Ghent

Local Institution, Hospitalet Llobregat- Barcelona

Columbia University Medical Center (Cumc), New York

Weill Cornell Medical College, New York

Local Institution, Milan

Local Institution, Bergamo

Local Institution, Madrid

Hospital Universitario La Paz, Madrid

Winship Cancer Center, Atlanta

Hopital Saint Eloi, Montpellier

Local Institution, Rennes

Local Institution, Salamanca

Vanderbilt-Ingram Cancer Center, Nashville

Local Institution, Bologna

Local Institution, Essen

Mayo Clinic, Rochester

Local Institution, Homburg

Local Institution, Pierre-Bénite

Local Institution, Napoli

Huntsman Cancer Institute, Salt Lake City

Mayo Clinic Arizona, Phoenix

Local Institution, Ulm

Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles

Local Institution, Erlangen

Local Institution, Créteil

Local Institution, Singapore

Local Institution, Singapore

Dana Farber Cancer Institute, Boston

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Local Institution, Waratah

Local Institution, Montreal

Local Institution, Montreal

Local Institution, Roma

Local Institution, Amsterdam

Local Institution, Rotterdam

Local Institution, Rotterdam

Local Institution, Utrecht

Local Institution, Gothenburg

Local Institution, Lund

Local Institution, Southampton

Local Institution, Withington

Local Institution, Sutton